Dose-dependent salidiuretic efficacy of torasemide in comparison to furosemide and placebo in advanced renal failure.
In a controlled randomized double-blind clinical trial the salidiuretic efficacy of 20 and 100 mg torasemide (1-isopropyl-3-([4-(3-methyl-phenylamino)pyridine]-3-sulfonyl)urea) and 60 mg furosemide, respectively, was compared including a control group with placebo after a single i.v. administration in 46 patients with advanced chronic renal failure (creatinine clearance less than or equal to 30 ml/min). 20 mg torasemide exerted a significant natriuretic activity within the first 6 h, whereas 100 mg torasemide induced a significant 24-h extra-excretion if compared to placebo. The sodium excretion induced by 100 mg torasemide was superior to the one by 60 mg furosemide. The duration of action of torasemide was longer than that of furosemide. The tolerance was good in all groups.
Mourad
G
G
Department of Nephrology, University Hospital of Montpellier, France.
Haecker
W
W
Mion
C
C
D000328:Adult; D000368:Aged; D002986:Clinical Trials as Topic; D003404:Creatinine / Q000652:urine; D004232:Diuretics / Q000009:adverse effects / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D004573:Electrolytes / Q000652:urine; D005260:Female; D005665:Furosemide / Q000627:therapeutic use*; D005919:Glomerular Filtration Rate; D006801:Humans; D007676:Kidney Failure, Chronic / Q000188:drug therapy* / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D011897:Random Allocation; D013449:Sulfonamides / Q000009:adverse effects / Q000627:therapeutic use*; D000077786:Torsemide
D004232:Diuretics; D004573:Electrolytes; D013449:Sulfonamides; D005665:Furosemide; D003404:Creatinine; D000077786:Torsemide